New CCO Module: Update of HCV Resistance from AASLD 2011

New Clinical Care Options CME Module now online: Update on HCV Resistance from AASLD 2011
Christoph Sarrazin, MD, reviews new data on resistance to direct-acting antiviral agents from the 2011 American Association for the Study of Liver Diseases conference. (Registration required)

Topics covered include:

New data on resistance to boceprevir and telaprevir
New data on resistance to second-wave and second-generation HCV protease inhibitors
Key findings on resistance to daclatasvir, an NS5A inhibitor
Current understanding of resistance to PSI-7977, a nucleotide polymerase inhibitor
New data on resistance to oral combination HCV therapies